Cancer Genetics (CGIX) Earns News Sentiment Score of 0.11

Media headlines about Cancer Genetics (NASDAQ:CGIX) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cancer Genetics earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 45.3830319747178 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

How to Become a New Pot Stock Millionaire

Several research analysts have commented on the stock. Maxim Group downgraded shares of Cancer Genetics from a “buy” rating to a “hold” rating and set a $6.00 price objective for the company. in a report on Tuesday, April 3rd. HC Wainwright set a $6.00 price target on shares of Cancer Genetics and gave the company a “buy” rating in a report on Tuesday, February 6th. Finally, ValuEngine raised shares of Cancer Genetics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. Cancer Genetics presently has a consensus rating of “Hold” and a consensus price target of $5.56.

Shares of NASDAQ:CGIX traded down $0.25 during trading on Monday, reaching $0.95. The company’s stock had a trading volume of 499,182 shares, compared to its average volume of 155,985. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.02. Cancer Genetics has a 12 month low of $0.90 and a 12 month high of $4.78. The company has a market cap of $33.30, a price-to-earnings ratio of -1.20 and a beta of 1.22.

WARNING: This news story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at

About Cancer Genetics

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Insider Buying and Selling by Quarter for Cancer Genetics (NASDAQ:CGIX)

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.

Leave a Reply